New Findings on Breast Cancer from Koch Institute for Integrative Cancer Research Summarized (Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment)
By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Oncology have been published. According to news reporting originating from Cambridge, Massachusetts, by NewsRx correspondents, research stated, "A single nanoparticle platform has been developed through the modular and controlled layer-by-layer process to codeliver siRNA that knocks down a drug-resistance pathway in tumor cells and a chemotherapy drug to challenge a highly aggressive form of triple-negative breast cancer. Layer-by-layer films were formed on nanoparticles by alternately depositing siRNA and poly-l-arginine; a single bilayer on the nanoparticle surface could effectively load up to 3500 siRNA molecules, and the resulting LbL nanoparticles exhibit an extended serum half-life of 28 h."
Our news editors obtained a quote from the research from Koch Institute for Integrative Cancer Research, "In animal models, one dose via intravenous administration significantly reduced the target gene expression in the tumors by almost 80%. By generating the siRNA-loaded film atop a doxorubicin-loaded liposome, we identified an effective combination therapy with siRNA targeting multidrug resistance protein 1, which significantly enhanced doxorubicin efficacy by 4 fold in vitro and led to up to an 8-fold decrease in tumor volume compared to the control treatments with no observed toxicity. The results indicate that the use of layer-by-layer films to modify a simple liposomal doxorubicin delivery construct with a synergistic siRNA can lead to significant tumor reduction in the cancers that are otherwise nonresponsive to treatment with Doxil or other common chemotherapy drugs."
According to the news editors, the research concluded: "This approach provides a potential strategy to treat aggressive and resistant cancers, and a modular platform for a broad range of controlled multidrug therapies customizable to the cancer type in a singular nanoparticle delivery system."
For more information on this research see: Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. Acs Nano, 2013;7(11):9571-84. (American Chemical Society - www.acs.org; Acs Nano - www.pubs.acs.org/journal/ancac3)
The news editors report that additional information may be obtained by contacting Z.J. Deng, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology , Rm 76-553, Cambridge, Massachusetts 02139, United States. Additional authors for this research include S.W. Morton, E. Ben-Akiva, E.C. Dreaden, K.E. Shopsowitz and P.T Hammond (see also Oncology).
Keywords for this news article include: Cambridge, Massachusetts, United States, North and Central America, Breast Cancer, Emerging Technologies, Genetics, Nanoparticle, Nanotechnology, Oncology, Small Interference RNAs, Women's Health, siRNA.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC